Thursday, February 24, 2011

Patient Reported Outcomes in Friedreich's Ataxia Patients After Withdrawal From Treatment With Idebenone (PROTI)

First Received: February 22, 2011 Last Updated: February 23, 2011

Sponsor: Santhera Pharmaceuticals
Information provided by: Santhera Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01303406

Locations: United Kingdom, The National Hospital, University College London

Principal Investigator: Paola Giunti, M.D, Institute of Neurology, The National Hospital, University College London

The potential application of iron chelators for the treatment of neurodegenerative diseases.

Metallomics. 2011 Feb 22. [Epub ahead of print]

Hider RC, Roy S, Ma YM, Le Kong X, Preston J.

King's College London, Institute of Pharmaceutical Science, London

Keywords: neurodegenerative disease, Alzheimer's disease, Parkinson's disease, Friedreich's ataxia, Hallervorden Spatz syndrome and macular degeneration, redox active metals, copper, iron, selective chelation.